Staging biomarkers in preclinical autosomal dominant Alzheimer's disease by estimated years to symptom onset.

DISCUSSION: Duration of each preclinical stage can be estimated in ADAD, facilitating better planning of prevention trials with the EYO cutoffs under the recently released FDA guidance. The generalization of these results to sporadic AD warrants further investigation.
PMID: 30773445 [PubMed - as supplied by publisher]

Source: The Journal of Alzheimers Association - February 20, 2019 Category: Psychiatry Tags: Alzheimers Dement Source Type: research